Clinical Trial Update: Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study of ruxolitinib in solid organ transplant recipients with advanced cutaneous squamous cell carcinoma was terminated, and results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Columbia University | Conditions: Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-12-27